Study investigates the antigenic and viral receptor-binding properties of major Omicron BA.2.75 subvariants biorxivpreprint ColumbiaPS UMich Omicron COVID19 coronavirus covid viral SARSCoV2 virus
By Tarun Sai LomteMar 28 2023Reviewed by Lily Ramsey, LLM *Important notice: bioRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
Further, BA.2.75-derived sub-variants are relatively diverse and have different evolutionary pathways. CH.1.1 and BN.1 are the most frequently observed sub-variants of Omicron BA.2.75. Several BA.2.75 sub-variants, including DS.1, CH.1, and CH.1.1, exhibited lower affinity than BA.2.75. Additional single substitutions in the BA.2.75 spike enhanced binding affinity.
BN.1 was relatively resistant to a few class 3 RBD mAbs. Notably, CH.1.1, CH.1, DS.1, BM.4.1.1, and BA.2.75.2 were highly resistant to neutralization by class 1 and class 2 RBD mAbs and most class 3 mAbs. Besides, BM.4.1, BM.4.1.1, CH.1, BN.1, DS.1, and BL.1 sub-variants significantly impaired neutralizing activity. The authors observed a similar trend for sera from bivalent vaccine recipients and BA.2 and BA.4/5 breakthrough cohorts. CH.1, DS.1, and CH.1.1 displayed substantially stronger evasion, while BN.1, BA.2.75.2, BL.1, BM.4.1.1 exhibited moderately higher evasion than BA.2.75.
BA.2.75.2 was 5.07 AUs from bivalent vaccine-boosted sera and 1.96 AU away from BA.4/5, suggesting an evasion advantage over BA.4/5. In addition, DS.1, CH.1.1, and CH.1 were 6.4, 6.75, and 6.09 AUs from the bivalent sera, respectively, similar to that for XBB.1.5 . The BA.2.75 sub-variants formed two antigenically distinct clusters; one set clustered with BQ sub-variants and the other with XBB sub-variants.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
SARS-CoV-2 reinfection uncommon among individuals with evidence of previous infection during the pre-vaccine eraSARS-CoV-2 reinfection uncommon among individuals with evidence of previous infection during the pre-vaccine era PLOSONE theNCI SARSCoV2 reinfection infection covid coronavirus COVID19 vaccine
Read more »
Epigenome reprogramming after SARS-CoV-2 infectionEpigenome reprogramming after SARS-CoV-2 infection Chromatin SARSCoV2 Coronavirus Disease COVID NatureMicrobiol UTHealthHouston MDAndersonNews SanDiegoBiomed
Read more »
What is the effect of prior BCG vaccination on the immunogenicity and efficacy of subsequent COVID-19 vaccination?What is the effect of prior BCG vaccination on the immunogenicity and efficacy of subsequent COVID-19 vaccination? biorxivpreprint mcgillu UofT universitelaval vaccine vaccination COVID19 coronavirus covid
Read more »
Getting COVID-19 Could Weaken Your Immune SystemA study illustrates how SARS-CoV-2 can damage your immune response
Read more »
Is nirmatrelvir treatment of SARS-CoV-2 associated with a lower risk of post–COVID-19 condition?Is nirmatrelvir treatment of SARS-CoV-2 associated with a lower risk of post–COVID-19 condition? JAMAInternalMed WUSTLmed STLOUISVA SARSCoV2 covid COVID19 coronavirus longcovid disease infection immunology
Read more »
Global population could fall to six billion with 'unprecedented investment' in tackling poverty, researchers sayThe forecasts in the report are in contrast to UN predictions which show the population reaching 9.7 billion in 2050 and peaking at 10.4 billion in the 2080s.
Read more »